Pharmaceutical Industry in the
Canton of Vaud

LE CHEM ORGANICS SA

Since 1972 · 1–10 empl.

The core activity of Le Chem Organics SA is the development, manufacture and distribution of fine chemicals, in particular pharmaceutical intermediates, active ingredients and organophosphorus compounds.

Sincopharm S.A.

Since 1989 · 11–20 empl.

The core activity of Sincopharm is the development, manufacturing, and packaging of cosmetic products. This includes: Research and development (R&D) of individual and exclusive formulations for cosmetic products; Manufacturing of cosmetic products in various galenics (emulsions, gels, balms, lotions, etc.) in compliance with "Good Manufacturing Practices" (GMP) according to ISO 22716; Packaging of cosmetic products with a special machine that allows vacuum filling and ensures optimal quality; Consulting and support in the selection of packaging and in the regulation of cosmetic products. Overall, Sincopharm offers a comprehensive range of services for the development, manufacturing, and packaging of cosmetic products that meet the high standards of Swiss quality.

Haleon CH SARL

Since 1991 · 21–50 empl.

Haleon CH SARL is a consumer health company focused on products for everyday health. The company develops and markets brands and solutions in areas such as oral health, pain relief and vitamins and supplements.

Matrixsanos Sàrl

Since 1996 · 1–10 empl.

Matrixsanos Sàrl manufactures chromopuncture instruments, ultrasonic devices to deter martens, and instruments for producing silver and copper colloids. The company supplies specialized products for therapists and for personal use.

Pharmacie des hôpitaux du Nord vaudois et de la Broye (PHNVB)

Since 1998 · 21–50 empl.

The core activity of the company "Pharmacie des Hôpitaux du Nord vaudois" (PHNVB) consists of the manufacture and distribution of pharmaceutical products, in particular: * Manufacture of sterile and non-sterile products * Preparation of cytostatics * Pharmaceutical support and clinical pharmacy * Research and development in the field of pharmacy The company is part of the healthcare system and works closely with the Hôpitaux du Nord vaudois to provide patients with the necessary medications and pharmaceutical services.

Ferring International Center SA

Since 2000 · 21–50 empl.

Ferring International Center SA is a biopharmaceutical company that develops and markets medicines and solutions in reproductive medicine and maternal health, gastroenterology, and urology. The website also describes research and development activities, clinical trials, and products for additional therapeutic areas.

Dompé International SA

Since 2002 · 1–10 empl.

Dompé International SA is a biopharmaceutical company engaged in research, development and manufacturing of medicines. It focuses on ophthalmic, neurological and pain‑related indications, including development of recombinant human nerve growth factor (rhNGF), and employs virtual screening technologies such as the Exscalate platform for drug discovery.

FONDATION EUROVACC

Since 2002 · 11–20 empl.

The core activity of EuroVacc is the development of safe and effective vaccines against HIV and other infectious diseases through the promotion and support of international collaborations with leading vaccine researchers and developers in the public and private sectors.

Haut-Lac Ecole Internationale Bilingue SA

Since 2003 · 11–20 empl.

Thermo Fisher Scientific is a leading company in the life science industry, specializing in the development, manufacture and distribution of products and services for research, development and production of pharmaceuticals, biotechnology and environmental analysis. The company's core activities include research and development, manufacturing of laboratory equipment and supplies, diagnostics, pharmaceutical development and production, as well as environmental analysis.

Merck Performance Materials (Suisse) SA

Since 2003 · 101–500 empl.

Merck Performance Materials (Suisse) SA is part of the Merck Group and operates in Switzerland across the Healthcare, Life Science and Electronics businesses. The company develops and supplies products, technologies and services for research, medical applications, and electronics and semiconductor uses.

Copexis SA

Since 2004 · 11–20 empl.

The core activity of Copexis S.A. is consulting and supporting pharmaceutical development, particularly in the following areas: * Early-stage pharmaceutical development (from development candidate to clinical phase II) * Late-stage pharmaceutical development (clinical phase III and marketing authorization in Europe and Switzerland) * Strategic consulting and support for the implementation of solutions in the areas of: + Pharmaceutical manufacturing + Toxicology + Clinical trials + Regulatory affairs * Regulatory services (CH/EU) * Corporate development and management Copexis positions itself as a strategic partner for companies in the pharmaceutical industry, offering comprehensive consulting and support for pharmaceutical development.

EFFIK SA

Since 2006 · 11–20 empl.

EFFIK SA is a pharmaceutical company specializing in the development, manufacture, and distribution of medicines, medical devices, and dietary supplements. The company's core activities include: * Research and development of new therapies and products, particularly in the fields of gynecology, neurology, hematology, and cardiology * Manufacturing and distribution of medicines, medical devices, and dietary supplements * Development of solutions for specific patient groups, such as women in various life situations (e.g. pregnancy, menopause) * Collaboration with medical experts and physicians to develop innovative solutions and improve patient care The company focuses on developing products tailored to the specific needs of patients and healthcare providers, and values quality, innovation, and patient proximity.

Ferring Pharmaceuticals SA

Since 2007 · 101–500 empl.

Ferring Pharmaceuticals SA is a biopharmaceutical company that develops medicines and therapies for gastroenterology, urology and reproductive medicine. The company conducts research, clinical development and maintains a product pipeline.

AMAZENTIS SA

Since 2007 · 51–100 empl.

AMAZENTIS SA develops clinically studied nutritional ingredients and consumer health products targeting cellular and mitochondrial health and age-related declines in muscle function. The company markets its proprietary ingredient Mitopure through the Timeline® consumer brand and lists Nestlé Health Science as a global strategic partner.

PRECLIN Biosystems SA

Since 2008 · 1–10 empl.

PRECLIN Biosystems SA provides a comprehensive in vivo preclinical testing platform for the identification and validation of lead therapeutic candidates and specializes in preclinical models of chronic inflammatory and infectious diseases.

NovaPharm SA

Since 2008 · 1–10 empl.

NovaPharm SA provides consulting, services and trading in the healthcare sector, including market access, distribution, sourcing and regulatory compliance. The company conducts purchase and resale of medicines and health products and holds a Swissmedic authorization for trading.

Excellness Biotech SA

Since 2009 · 1–10 empl.

Excellness Biotech SA develops biomimetic cell culture substrates with defined elasticity for laboratory use. The company offers soft culture surfaces and wrinkling substrates used to study cell behavior and contraction.

HRA-Pharma Switzerland Sàrl

Since 2009 · 1–10 empl.

HRA-Pharma Switzerland Sàrl is a company active in self-care and consumer health products. The website presents products and solutions for conditions that can be self-managed or prevented, including areas such as cold and respiratory care, pain relief, skincare, oral care and women's health.

Asceneuron SA

Since 2012 · 11–20 empl.

The core activity of Asceneuron SA is the development of innovative small molecules and Tau modifiers for the treatment of diseases, particularly in the area of the central nervous system (CNS). The company focuses on the early stages of drug development and conducts clinical trials to test the efficacy and safety of its active ingredients.

Laboratoire Pharmessence, Luc-Henri Geny

Since 2013 · 1–10 empl.

Pharmessence is a laboratory specializing in the manufacture and distribution of plant-based medicines and products for phytotherapy and aromatherapy. The company's core activity encompasses the development and production of: plant-based preparations (e.g. essential oils, hydrolats, vegetable oils, lipid extracts); magistral preparations for pharmacies; and medicinal products based on plant extracts. The company primarily offers its products to professional customers, such as pharmacies and medical professionals.

fondation Innovative Medicines for Tuberculosis (iM4TB)

Since 2014 · 11–20 empl.

The core activity of iM4TB is the development of innovative medicines to combat tuberculosis. The company researches and develops new treatment methods and agents to eliminate tuberculosis.

Floratek Pharma SA

Since 2015 · 11–20 empl.

The core activity of Floratek Pharma is the discovery and development of new therapeutic active ingredients based on plant ingredients for the treatment of diseases, particularly in the field of cancer and central nervous system diseases. The company uses artificial intelligence and computer-aided models to design and optimize small molecules that specifically influence biological processes, thus offering new treatment options for various diseases.

Combioxin SA

Since 2015 · 11–20 empl.

The core activity of Combioxin SA is the development of life-saving medications for severe infections, particularly for the treatment of severe bacterial pneumonias. The company focuses on the development of innovative therapeutics, such as CAL02, a first-in-class anti-toxin agent used to neutralize virulence factors that play a crucial role in the development of organ failure and fatal complications in severe infections.

Hartis-Pharma SA

Since 2016 · 11–20 empl.

The core activity of HARTIS Pharma consists of researching and developing therapeutics based on the potential benefits of High-Density-Lipoprotein (HDL), particularly through the regulation of membrane cholesterol and its liposoluble cargo activity of antioxidants. The company focuses on developing treatments for medical needs that have not been adequately addressed or cannot be treated sufficiently.

Axalbion SA

Since 2017 · 11–20 empl.

Axalbion SA is a clinical-stage biopharmaceutical company developing TRPM8 agonists. Its lead candidate AX-8 is being developed for topical treatment of refractory chronic cough and dry eye syndrome.

Fresenius Kabi SwissBioSim GmbH

Since 2017 · 1–10 empl.

Fresenius Kabi SwissBioSim GmbH belongs to the Fresenius Kabi group and operates in healthcare. The company provides medicines, infusion therapy, medical nutrition, MedTech solutions and biopharmaceuticals for the care of critically and chronically ill patients.

Swiss Medical Cannabis SA

Since 2017 · 11–20 empl.

Swiss Medical Cannabis SA sells hemp and cannabis products through an online shop and supplies these products via pharmacies and other retail partners.

Tigen Pharma SA

Since 2017 · 11–20 empl.

The core activity of Tigen Pharma is the development and acceleration of access to new therapies in the field of cell and gene therapy, particularly for the treatment of cancer. The company combines scientific expertise, technological capabilities and a long-term perspective to develop innovative solutions for patients and society.

iGreen Swiss SA

Since 2017 · 1–10 empl.

The core activity of iGreen Swiss S.A. is the development, production and distribution of medical cannabis and its derived products, in particular Tetrahydrocannabinol (THC) and Cannabidiol (CBD), for therapeutic purposes. The company is active in all phases of the value chain, from research and development to the manufacture and marketing of medical cannabis and its derived products.

Pharmotech SA

Since 2018 · 1–10 empl.

The core activity of Pharmotech SA is the research and development of medical products based on plant-based active ingredients, particularly CBD, to combat multi-resistant bacteria (MDR-MRSA). The company focuses on researching and developing innovative solutions to combat bacteria such as Pseudomonas Aeruginosa and Staphylococcus Aureus.

LAM Biotechnologies SA

Since 2018 · 1–10 empl.

LAM Biotechnologies SA is a biotechnology company focused on research and development, production of its own products, and sales and marketing of those products. It also provides services in diagnostics, platform technologies, analytical testing, screening, and bioinformatics.

Bial SA

Since 2018 · 21–50 empl.

The core activity of BIAL is the development, manufacture and marketing of medicines and therapeutic solutions in the healthcare sector. The company focuses particularly on research and development of new medicines and therapies to improve the quality of life of people worldwide.

Haya Therapeutics SA

Since 2019 · 21–50 empl.

The company develops precise therapeutics based on genome research and biotechnology. It focuses on the development of medicines and therapies, particularly in the field of cardiovascular diseases and regenerative medicine. The core activity includes research and development of new medicines, identification and evaluation of new business opportunities, conducting due diligence reviews, and managing portfolio companies.

Onward Therapeutics SA

Since 2019 · 1–10 empl.

The core activity of Onward Therapeutics is the development of innovative cancer treatments, particularly through the identification and development of potential active substances and technologies in the field of immunotherapy and oncology. The company focuses on the development of drugs that support the immune system to fight cancer, and works with partners to develop and market transformative technologies.

Orgenesis Switzerland Sàrl

Since 2020 · 11–20 empl.

Orgenesis Switzerland Sàrl develops and implements the POCare platform for cell and gene therapies, focusing on process development, validation and automated closed‑loop bioprocessing units (OMPUL™) for decentralized point‑of‑care production.

Atreon SA

Since 2021 · 1–10 empl.

Atreon SA develops AI-driven digital health solutions, including digital biomarkers and mobile and web platforms for remote monitoring of musculoskeletal and chronic pain conditions. The company collaborates with academic partners on patient-centric design, algorithm development, data safety and real-world evidence generation.

Horus Pharma Suisse SA

Since 2021 · 101–500 empl.

The core activity of Horus Pharma is the development, manufacture and marketing of pharmaceuticals, medical devices and dietary supplements, particularly in the fields of ophthalmology, dermatology and surgery. The company focuses on creating therapeutic solutions and accompanying services for doctors and patients, with an emphasis on innovation, ethics and patient benefit.

Vandria SA

Since 2021 · 21–50 empl.

Vandria SA is a clinical-stage biotech company developing first-in-class small molecules against a novel metabolic target to restore mitochondrial function and reduce chronic inflammation for the treatment of age-related and chronic diseases. Its lead clinical CNS asset, VNA-318, is an orally available, brain-penetrant small molecule that completed Phase I studies demonstrating safety, tolerability and a pharmacokinetic profile suitable for once-daily oral dosing.